Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;44(4):1589-1596.
doi: 10.1007/s10067-025-07393-0. Epub 2025 Mar 10.

Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort

Annik Steimer  1 , Andrea Götschi  2 , Torsten Witte  3 , Almut Scherer  2 , Jonas Brändli  2 , Michael J Nissen  4 , Burkhard Möller  5 , Simon Grosswiler  6 , Diego Kyburz  7 , Diana Dan  8 , Andrea Rubbert-Roth  9 , Sabine Adler  10 , Oliver Distler  11 , Xenofon Baraliakos  12 , Adrian Ciurea  11
Affiliations

Anti-CD74 autoantibodies in axial spondyloarthritis as biomarkers for activity and severity of disease but not for tumour necrosis factor inhibitor retention: data from the Swiss Clinical Quality Management in rheumatic diseases cohort

Annik Steimer et al. Clin Rheumatol. 2025 Apr.

Abstract

Objectives: Anti-CD74 antibodies (Abs) have been proposed as a diagnostic biomarker in axial spondyloarthritis (axSpA). The aims of this study were to evaluate the association of these Abs with disease activity parameters in axSpA and to assess their predictive value for tumour necrosis factor inhibitor (TNFi) treatment effectiveness.

Methods: Patients diagnosed with axSpA in the Swiss Clinical Quality Management registry with available biosamples and a measurement of IgA anti-CD74 Abs were included in this cohort study. We used a cut-off of 15 U/ml to define anti-CD74 Abs elevation. Associations of important disease characteristics with anti-CD4 Abs elevation and anti-CD74 Abs levels were evaluated using logistic and linear regression, respectively. For patients with an available biosample before TNFi initiation, we evaluated drug retention and estimated the hazard ratio of treatment discontinuation depending on anti-CD74 Abs elevation.

Results: Elevated IgA anti-CD74 Abs were found in 383/722 (53%) patients with axSpA and were significantly associated with older age, male sex, and elevated C-reactive protein (CRP). Among 310 patients starting TNFi treatment, no significant difference in drug retention was found between patients with and without elevated anti-CD74 Abs (HR 0.91, 95% CI 0.66 to 1.25). An increased Bath Ankylosing Spondylitis Disease Activity Index was found to be associated with a reduced TNFi retention whereas an elevated CRP was associated with a prolonged retention.

Conclusions: Although elevated IgA anti-CD74 Abs are associated with CRP elevation, we could not demonstrate an additional value of this biomarker for predicting response to treatment with TNFi beyond CRP measurement.

Keywords: Axial spondyloarthritis; Cohort study; IgA anti-CD74 antibodies; TNF inhibitor treatment.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical standards: The study has been approved by the ethics committee and has therefore been performed in accordance with the ethical standards laid down in the Declaration of Helsinki. All persons gave their informed consent prior to the inclusion in the study. Conflict of interest: AnS is supported by the MLR foundation. AG: None. TW: Honoraria for lectures and consultation from Abbvie, Alfasigma, Amgen, Janssen, Lilly, Medac, MSD, Novartis, Pfizer, UCB. Patent on CD74 autoantibody measurement. AlS: None. JB: None. MJN: Honoraria for lectures and consultation from Abbvie, Janssen, Eli Lilly, Novartis, Pfizer, and UCB. BM: None. SG: None. DK: Honoraria for lectures and consultation from Abbvie, Eli-Lilly, Janssen, Novartis, Pfizer, Roche, Sanofi. DD: None. ARR: Honoraria for lectures and consultation from Abbvie, Janssen, MSD, Novartis, Pfizer, UCB. SA: None. OD: None. XB: None. AC: None.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve of tumour necrosis factor inhibitor retention. Estimated survival curve of patients with elevated IgA anti-CD74 antibodies and patients without elevated IgA anti-CD74 antibodies. Median retention times are represented by vertical lines. 65 patients with elevated and 53 without elevated IgA anti-CD74 antibodies were censored. Anti-CD74 IgA = Anti-CD74 Immunoglobulin A
See this image and copyright information in PMC

References

    1. Baerlecken NT, Nothdorft S, Stummvoll GH, Sieper J, Rudwaleit M, Reuter S et al (2014) Autoantibodies against CD74 in spondyloarthritis. Ann Rheum Dis 73:1211–1214. 10.1136/annrheumdis-2012-202208 - DOI - PubMed
    1. Baraliakos X, Baerlecken N, Witte T, Heldmann F, Braun J (2014) High prevalence of anti-CD74 antibodies specific for the HLA class II-associated invariant chain peptide (CLIP) in patients with axial spondyloarthritis. Ann Rheum Dis 73:1079–1082. 10.1136/annrheumdis-2012-202177 - DOI - PubMed
    1. Ranganathan V, Ciccia F, Zeng F, Sari I, Guggino G, Muralitharan J et al (2017) Macrophage migration inhibitory factor induces inflammation and predicts spinal progression in ankylosing spondylitis. Arthritis Rheumatol 69:1796–1806. 10.1002/art.40175 - DOI - PubMed
    1. Starlets D, Gore Y, Binsky I, Haran M, Harpaz N, Shvidel L et al (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107:4807–4816. 10.1182/blood-2005-11-4334 - DOI - PubMed
    1. Sogkas G, Klose K, Baerlecken N, Schweikhard E, Matthias T, Kniesch K, et al. (2020) CD74 is a T cell antigen in spondyloarthritis. Clin Exp Rheumatol 38:195–202. 10.55563/clinexprheumatol/lezc69 - PubMed

MeSH terms